STAT3 and prostate carcinoma: Collectively, our results identify a novel, ETV1‐dependent, oncogenic pathway in prostate cells and highlight the potential therapeutic outcome of coinhibition of EGFR and STAT3 in prostate carcinomas with ETV1 overexpression.